
1. j vis exp. 2016 feb 28;(108):53670. doi: 10.3791/53670.

development alpha-synuclein based rat model parkinson's disease via
stereotactic injection recombinant adeno-associated viral vector.

van der perren a(1), casteels c(2), van laere k(2), gijsbers r(3), van den haute 
c(4), baekelandt v(5).

author information: 
(1)laboratory neurobiology gene therapy, department neurosciences, ku 
leuven.
(2)division nuclear medicine, leuven university hospital - ku leuven.
(3)laboratory molecular virology gene therapy, department of
pharmaceutical pharmacological sciences, ku leuven; leuven viral vector core,
ku leuven.
(4)laboratory neurobiology gene therapy, department neurosciences, ku 
leuven; leuven viral vector core, ku leuven.
(5)laboratory neurobiology gene therapy, department neurosciences, ku 
leuven; veerle.baekelandt@med.kuleuven.be.

in order study molecular pathways parkinson's disease (pd) to
develop novel therapeutic strategies, scientific investigators rely animal
models. identification pd-associated genes led development of
genetic pd models. transgenic α-syn mouse models develop gradual α-syn
pathology fail display clear dopaminergic cell loss dopamine-dependent
behavioral deficits. hurdle overcome direct targeting the
substantia nigra viral vectors overexpressing pd-associated genes. local
gene delivery using viral vectors provides attractive way express
transgenes central nervous system. specific brain regions targeted 
(e.g. substantia nigra), expression induced adult setting and
high expression levels achieved. further, different vector systems based
on various viruses used. protocol outlines crucial steps to
perform viral vector injection substantia nigra rat develop 
viral vector-based alpha-synuclein animal model parkinson's disease.

doi: 10.3791/53670 
pmcid: pmc4828209
pmid: 26967677  [indexed medline]

